Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients

Arzneimittelforschung. 2011;61(6):335-9. doi: 10.1055/s-0031-1296207.

Abstract

The aim of the present study was to determine the prescribing practice for clozapine (CAS 5786-21-0) as well as the plasma levels of clozapine and its main metabolite norclozapine (CAS 6104-71-8) in Mexican patients. A prospective study was performed in 69 in and out psychotic patients taking clozapine. Blood samples were taken at steady state. Plasma concentrations of clozapine and norclozapine were determined by HPLC. The results showed that the mean daily dose administered was 250 mg/d. Plasma levels showed a large interindividual variability. Mean plasma levels were 411.3 +/- 328.12 ng/mL, for clozapine and 172.0 +/- 129.9 ng/mL for norclozapine. When data were compared with those reported in other populations, it was found that although the dose was lower than that reported in Caucasians, the plasma levels were similar. As a result, the predictive models for the estimation of clozapine concentration in Caucasians were not appropriate for application in Mexican patients. The findings suggest ethnic differences in the ratio dose/plasma levels of clozapine in Mexican patients. Further studies are required to expand the observations.

MeSH terms

  • Adult
  • Aged
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / blood*
  • Antipsychotic Agents / pharmacokinetics
  • Chromatography, High Pressure Liquid
  • Clozapine / adverse effects
  • Clozapine / analogs & derivatives*
  • Clozapine / blood
  • Clozapine / pharmacokinetics
  • Drug Monitoring
  • Ethnicity
  • Female
  • Humans
  • Male
  • Mexico
  • Middle Aged
  • Prospective Studies
  • Schizophrenia / blood*

Substances

  • Antipsychotic Agents
  • norclozapine
  • Clozapine